Penny Press Releases & SEC Filings

[cableguy]

AGIJ: Collagenna (AGIJ) Receives Positive Test Results on New Professional Product
Date : 03/14/2011 @ 3:45PM
Source : MarketWire
Stock : Axia Group Inc. (AGIJ)
Quote : 0.0025 0.0008 (47.06%) @ 4:02PM

Collagenna (AGIJ) Receives Positive Test Results on New Professional Product
Axia Group New (USOTC:AGIJ)
Intraday Stock Chart

Today : Monday 14 March 2011
Click Here for more Axia Group New Charts.

Axia Group (PINK SHEETS: AGIJ) (http://www.axiacorporation.com/) Collagenna Skin Care Products new Professional Peptide Serum was tested by one of its US partners, The Texas Beauty Institute (TBI) http://www.texasbeautyinstitute.com with positive results.

The Texas beauty Institute has completed an observational study on the Collagenna 40% Professional Peptide formula with 10 aesthetic patients using only non-invasive techniques. The purpose of the study was to determine whether the formula would provide further improvement on candidates who: a.) were early in their non-invasive treatment regiment, and b.) had completed their initial series of microcurrent treatments and were on a maintenance schedule.

Candidates:

Group A: 5 early candidates ages ranged from 36 to 66,

Group B: 5 maintenance schedule candidates ranged from 42 to 64,

Due to the potency of the formula, TBI's preferred application was infusion methodologies iontophoresis or sonophoresis after preparation with TBI's proprietary MCR Conduction Gel™.

Results:

All 10 candidates obtained a "softening" of features, however the most dramatic results were observed with candidates with more pronounced wrinkles - typically the older patients in both groups. Of significant note were 3 patients from Group B that had received at least 10 microcurrent treatments previously and considered to have reached a "plateau" of improvement. In these 3 candidates additional improvement was noted in the overall skin tone, reduction of wrinkles and most notable an overall softening of features. As an adjunct with Group A candidates, the improvements were acceptable but less dramatic.

As a result of these observations, TBI will introduce a new infusion peptide protocol to accompany TBI's proprietary Elastin Infusion Therapy.

TBI President Nelson Thibodeaux said, "TBI looks forward to introducing the US market to this additional innovative, non-invasive, effective treatment protocol. We know our professional skin care market will appreciate this new significant anti-aging resource for their clients and patients. We look forward to continuing innovative development of products and protocols with Collagenna."

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Axia Group Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Axia Group Inc. cautions you that any forward-looking information provided by or on behalf of Axia Group Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Axia Group Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Axia Group Inc.'s control. In addition to those discussed in Axia Group Inc.'s press releases, public filings, and statements by Axia Group Inc.'s management, including, but not limited to, Axia Group Inc.'s estimate of the sufficiency of its existing capital resources, Axia Group Inc.'s ability to raise additional capital to fund future operations, Axia Group Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Axia Group Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Axia Group Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contacts:

Axia Group Inc.

[e-mail]



Investor Relations

1-647-426-1640